A policy shift at the FDA has reshaped demand dynamics for estradiol transdermal patches, according to reporting tied to an apparent rethink of menopausal hormone therapy benefits. While U.S.-approved estradiol patch supply reportedly doubled over the past year, brand and generic manufacturers are said to be struggling to keep up with increased demand. The episode underscores how regulatory communications can move the supply chain quickly, forcing manufacturers to respond even when availability has recently improved. For biotech and healthcare stakeholders, it signals continued volatility in product utilization patterns following updates to benefit-risk perceptions. In practical terms, the situation is likely to affect prescribing behavior and commercial forecasting for women’s health products, and it may introduce additional operational pressure for distributors and pharmacy benefit stakeholders monitoring shortages and fulfillment timelines.